The p53 tumor suppressor is a member of a multi-protein family, including the p63 and p73 transcription factors. These proteins can bind to the same consensus sites in DNA and activate the same target genes, suggesting that there could be functional redundancy between them. Indeed, double mutant mice heterozygous for any two family member-encoding genes display enhanced cancer phenotypes relative to single heterozygous mutants. However, whether the family members play redundant roles during embryonic development has remained largely unexplored. Although p53
The p53 protein is a critical tumor suppressor, as indicated by the findings that p53 is mutated in over half of all human tumors and that p53-null mice develop cancer with complete penetrance. [1] [2] [3] [4] p53 is a transcription factor, which, when activated in response to various cellular stress signals, induces expression of numerous downstream targets important for its cellular functions, including cell-cycle arrest and apoptosis, mechanisms to limit cellular proliferation. 5 Although p53 knockout mice do not die until they succumb to tumors as adults, underscoring a predominant role for p53 in tumor suppression, [2] [3] [4] more careful inspection of p53-null embryos demonstrated that a subset display developmental phenotypes. 6, 7 In all, 8-16% of p53-null embryos, depending on the genetic background, die perinatally with the cranial neural tube closure defect exencephaly, a phenotype observed mostly in females. 6, 7 p53-null embryos also manifest partially penetrant defects in other structures, such as eyes and teeth. [7] [8] [9] This relatively minor role in development relative to tumor suppression contrasts with that of most tumor suppressor genes, whose knockout in mice typically provokes fully penetrant embryonic lethality. 10 Subsequent to the discovery of p53, two related transcription factors-p63 and p73-were identified. 11 The three proteins exhibit significant sequence similarity in their sequence-specific DNA-binding (~63%), oligomerization (~37%) and transactivation (~22%) domains and can bind to the same consensus sites in DNA and activate the same target genes. 11 However, unlike p53, with a paramount role in cancer suppression, p63 and p73 play more central developmental roles. p63-nullizygosity results in perinatal lethality accompanied by a failure of stratified epithelium and limb development, and by craniofacial and skeletal defects.
12,13
p73-nullizygosity results in lethality within several weeks after birth, along with a host of phenotypes, including reduced size, hippocampal dysgenesis, hydrocephalus, chronic infections and inflammation, and pheromone-sensing defects that impede breeding. 14 At least some of these phenotypes are attributable to defects in multiciliogenesis. 15, 16 Given the similarity to p53, a role for p63 and p73 in tumor suppression has also been investigated. While not found to be commonly mutated in human cancer, p63-or p73-heterozygous mice on some genetic backgrounds display a slightly increased predisposition to certain tumor types relative to wildtype mice, typically associated with loss of heterozygosity (LOH), 17 and Eμ-Myc mice heterozygous or null for p73 present with higher rates of lymphoma dissemination than control mice. 18 Moreover, compound mutant mice heterozygous for any two of the p53, p63, and p73 loci exhibit reduced tumor latency, higher tumor burden and enhanced rates of metastasis relative to single heterozygotes. 17, 19 Finally, p73 loss enhances the tumor predisposition of p53-null mice.
embryonic development. The lethality observed in singlefamily member knockout mice typically occurs after birth, and it may be that there is not a more dramatic phenotype in these knockouts during development because of redundancy or compensation between family members. In terms of expression patterns, p53 mRNA is expressed ubiquitously during early mouse development, but then exhibits a more restricted pattern in differentiating organs later in development. 20 p63 protein is expressed in the basal layer of various stratified epithelia, such as the epidermis, esophagus, bladder, and mammary gland, 12, 13, 21 whereas p73 RNA/protein is expressed primarily in the nervous system with some expression in testis germ cells and in specific epithelia such as the epidermis. 14, [22] [23] [24] Thus, these expression patterns suggest that the most likely tissues in which family members might play redundant functions would be epithelia such as the epidermis. Here, we address the redundancy between p53 family members during embryogenesis by intercrossing previously generated p53, p63, and p73 heterozygous mutant mice and analyzing the resulting compound mutant mice at various time points throughout development. 6, 13, 14 As previous studies have already reported that p53
compound male mice are born at Mendelian ratios, with compound mutant females displaying neonatal mortality due to the defects attributable to p53 loss, namely exencephaly, 19, 25 we have primarily analyzed the viability and developmental phenotypes of p53
−/− , and p63 −/− ;p73 −/− mice. 6, 13, 14 Analysis of compound null progeny from p53 +/ − ;p63
intercrosses revealed no viable mice at weaning, consistent with p63 −/− embryos displaying perinatal lethality due to dehydration caused by defects in epidermal stratification.
However, we observed near-expected Mendelian numbers of live p53 −/− ;p63 −/− embryos at both E10.5 and E16.5-E19.5, based on the presence of a heartbeat ( Figure 1a ). Wholemount and histological analyses of E10.5 and E16.5-E19.5 p53 −/− ;p63 −/− embryos revealed no obvious defects that would prevent late-stage viability (Figures 1b and 2a) . Specifically, heart, liver, lung, intestine, and neuronal development appeared grossly normal. In contrast, the characteristic p63-null phenotypes of limb, epithelial, and craniofacial defects were equally apparent irrespective of p53 status. Moreover, the remnants of epidermis in p53 −/− ;p63 −/− mutants did not appear less intact than in p63 −/− embryos, as assessed by histology and staining for the basal cell marker K14 (Figure 2d ). Thus, the combined loss of p53 and p63 in embryos does not appear to significantly compromise mouse development beyond simple p63 or p53 deficiency.
We next examined whether loss of both p63 and p73 has any effect on development. Interestingly, previous experiments examining p63 −/− ;p73 −/− MEFs suggested that combined p63 and p73-nullizygosity phenocopies p53 loss in apoptosis assays, both in the embryonic CNS and in oncogene-expressing fibroblasts. 26 Upon intercrossing p63 +/ − ; p73 +/ − mice, we observed no viable p63 −/− ;p73 −/− mice after birth, as expected from p63 deficiency. However, analyses of embryos late in embryogenesis at E16.5-E18.5 revealed viable p63 −/− ;p73 −/− embryos at normal Mendelian ratios ( Figure 1c ). Further analyses revealed limb, epithelial and craniofacial defects attributable to p63 loss (Figures 1d and   2b ). However, there were no apparent additional defects due to the added loss of p73, as heart, liver, lung, intestine, and neuronal development appeared globally normal. Notably, we did not observe any dramatic brain phenotypes that are sometimes observed in p73 −/− mice, such as hydrocephalus, although this could be due to low penetrance (~20%) and/or genetic background. 14, 15 In addition, the residual epidermis did not show any enhanced defects compared to the single mutants (Figure 2d) . Notably, compound p63 and p73 deficiency did not induce the exencephaly seen in some p53 −/− embryos, indicating that combined loss of p63 and p73 does not recapitulate p53 loss in the context of the neural tube. Thus, p63
−/− embryos showed no dramatic developmental defects beyond those observed in single knockout embryos.
Since double knockout of p53 family members did not significantly affect embryonic development, we sought to determine whether loss of any five alleles or all six alleles of the p53 family would result in any additional developmental defects. Given the poor odds of obtaining triple knockout embryos (1 in 64), we first examined the effects of loss of any five alleles of the p53 family on normal development (mice null for two genes and heterozygous for the remaining gene; 1 in 32 odds). We intercrossed p53 +/ − ;p63 +/ − ;p73 +/ − triple heterozygous mice and analyzed viability at mid-gestation. Analysis of embryos at both E10.5 and E13.5 revealed viable embryos of all possible combinations: p53
−/− ;p63 +/ − ;p73 −/− , and p53 +/ − ;p63 −/− ;p73 −/− , as determined by the presence of a heartbeat (Figure 1e ). Wholemount and histological analyses revealed only defects attributable to p63-nullizygosity (for example, limb and craniofacial defects), and, in a subset of embryos, defects associated with p53-nullizygosity (e.g. exencephaly) (Figures 1f and 2c) . Somite number and heart, liver, lung, and neuronal development appeared globally normal, suggesting that these embryos may also be viable at later stages of development. Thus, loss of five out of six alleles of the p53 family does not compromise development through mid-gestation. Surprisingly, we also identified a single p53
−/− embryo at E11.0, based on PCR analysis of both yolk sac and tail DNA (Figures 1e and g ). This triple knockout embryo was viable, as determined by the presence of a heartbeat. Whole-mount analysis of the triple knockout embryo uncovered only p63-null associated defects similar to a p63 −/− littermate and not the p53-null associated defect exencephaly (Figure 1h) . Although somite number, liver structure, and neural tube closure of this p53
−/− embryo looked developmentally typical, histological analyses of serial sections revealed hypomorphic cardiac cushion development relative to p63-null and other littermates (Figures 1h and 2e) . Collectively, these findings indicate that the p53 family members are not strictly necessary for early development, but that they may play redundant roles in specific developmental processes. Given the low odds of obtaining embryos of the triple knockout genotype, it is also difficult to ascertain to what extent these embryos might be underrepresented. Attempts to increase the odds of obtaining triple knockout embryos by using homozygous null breeders were complicated by the early mortality of p63-and p73-null mice, the high incidence of early cancer development in p53 family in mammalian development JL Van Nostrand et al p53-null mice, and the limited ability of p73-and p53-null mice to breed due to the absence of pheromone receptors and reduced fertility, respectively. [2] [3] [4] [12] [13] [14] 24, 27 In future, it will be important to attempt to analyze a larger cohort of triple knockout embryos to fully understand the role of the p53 family in development. Of note, given that p63 and p73 exist in different isoformsthe TA isoforms with a complete transactivation domain and the ΔN isoforms lacking the full TAD domain, and which typically inhibit the TA isoforms-it was formally possible that some phenotypes might have been rescued by compound deletion of multiple p53 family members. For example, if tissues where ΔNp63 expression predominates are defective in p63-null animals because TAp73 is no longer inhibited, then the proper development of these tissues would be restored in p63 −/− ;p73 −/− animals. However, in compound null embryos, we did not observe an amelioration of phenotypes typical of single mutants, suggesting that the lack of restraint of TA isoform function by ΔN isoform expression does not underlie the observed phenotypes.
Given that the p53 family members are highly conserved, with homologous DNA-binding domains that allow them to bind the same consensus sites and regulate common target genes, it was expected that there would be functional redundancy between these proteins during development. While combined p53 and p73 loss has previously been shown to be compatible with postnatal viability, 19, 25 we have now shown that loss of both p63 and p73 or p53 and p63 is compatible with viability until late gestation, with embryos manifesting only obvious defects characteristic of single mutants. The dispensability of the p53 family members for embryonic development is in stark contrast to the consequences of loss of other protein families during embryogenesis. For example, embryos with double knockout of members of the Rb family of cell-cycle regulators (Rb, p107, or p130) consistently display earlier lethality than single mutants, underscoring the redundant functions of family members during embryogenesis. [28] [29] [30] Furthermore, loss of all three Rb family members in the embryo elicits even more severe embryonic phenotypes. 31 Thus, all Rb family members play redundant roles that can be revealed in any double mutant, and even more dramatically upon complete loss of the Rb family. These findings highlight the importance of redundancy between members of multi-protein families involved in cell-cycle regulation and apoptosis to ensure proper embryonic development and underscore the surprising lack of earlier lethality or significantly exacerbated developmental defects in the compound p53 family member mutant embryos.
The surprising lack of clear redundancy between the p53 family members during embryogenesis could relate to lack of either overlapping expression or compensatory upregulation of specific family members when other family members are ablated. Notably, we cannot completely rule out potential redundancy between family members very late in embryogenesis or more subtle redundant roles in the development of specific organs such as the heart. Interestingly, the lack of redundancy we observe contrasts with the redundancy observed between p53 family members in tumor studies, where more severe cancer phenotypes are observed with deficiency of multiple family members. 17, 19 These findings suggest the importance of cooperative action of the p53 family in certain physiological contexts such as cancer suppression, but not during early embryogenesis. Future investigation will better elucidate the interplay between p53 family members in later development and tumor suppression.
NOTE
While this manuscript was in press, Wang et al. reported using blastocyst injection of triple knockout (TKO) mouse embryonic stem cells, generated by CRISPR/Cas9-mediated inactivation of p53, p63 and p73, into wild-type embryos to analyze the phenotype of TKO embryos (Cell Stem Cell 20, 70-86, 2017). They showed that chimeric embryos displayed severe morphological defects starting at~E7.5 and that the p53 family is essential for mesoendodermal differentiation. In contrast, using classical breeding strategies, we were able to identify one E11.0 p53 À / À ;p63 À / À ;p73 À / À embryo that appeared normal except for heart endocardial cushion defects. Our result does not exclude a phenotype in some TKO embryos given the limited number of embryos we were able to obtain by breeding, but it does indicate that a relatively normal TKO embryo can develop. The difference in our results may relate to genetic background or potentially to the additional time required for compensatory pathways to be upregulated in our system.
